Indication Includes Children Ages 6 Years and Older and Weighing at Least 30 kg
MONTREAL, March 28, 2024 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC:ENDPQ), today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years and older and weighing at least 30 kg with narcolepsy.
Read more at newswire.ca